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Abstract
Background: Induction chemotherapy incorporating docetaxel, cisplatin and 5- fluorouracil before radiotherapy
may improve the outcome of patients with advanced head and neck cancer. Nevertheless, the addition of
docetaxel increases hematological toxicity and infectious complications. Therefore, genetic markers predicting
toxicity and efficacy of this treatment regimen may help to identify patients, who would have the most benefit
from this intensive treatment.
Methods: A cohort of 78 patients with advanced head and neck cancer treated with induction chemotherapy was
assessed for clinical outcome and toxicity during treatment with curative intention. Genetic polymorphisms primary
associated with treatment efficacy (ERCC2-rs13181, rs1799793, ERCC1-rs3212986, rs11615, XRCC1-rs25487) or with
docetaxel caused toxicity (CYP39A1-rs7761731, SLCO1B3-rs11045585) were evaluated in all patients. The results of
these analyses were correlated with the clinical outcome of the patients (loco regional control, progression free
survival, overall survival) and treatment related toxicity during induction chemotherapy.
Results: Median progression free survival and overall survival was 20 and 31 months in an intention to treat
analysis, respectively. Overall response rate to induction chemotherapy was high with 78.1 % of all patients. None
of the polymorphisms tested was associated with the clinical outcome of the patients. Genotype A of the CYP39A1
rs7761731 polymorphism was associated with a higher incidence of leucopenia and infections or death during
induction chemotherapy.
Conclusions: Intensive induction chemotherapy results in a high response rate in the majority of patients. None of
the polymorphisms tested was associated with the clinical outcome of the patients. The CYP39A1 polymorphism
rs7761731 may help to identify patients at high risk for treatment related toxicity.
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Background
The management of patients with advanced head and
neck cancer is a complex process requiring a multidis-
ciplinary approach including effective cytotoxic regi-
mens, radical surgery and radiotherapy (RT) [1]. It has
been shown that patients with locally advanced disease
not suitable for surgery can be cured with induction
chemotherapy followed by definitive radiochemotherapy
(RCTX) [2]. Two randomized controlled phase III trials
showed an overall survival (OS) benefit for the addition
of docetaxel to induction chemotherapy with a platinum
compound and 5-fluorouracil (TPF) followed by RT with
or without low-dose carboplatin [3, 4]. Therefore, this
approach can be used in patients with locally advanced
disease not suitable for surgery although two recently
published trials doubt the clinical value of induction
treatment in comparison to primary RCTX [5, 6]. Fur-
thermore, the specific value of radio-sensitizing therapy
in addition to RT after TPF is unclear.
This intensive treatment strategy is also associated
with significant toxicity. Furthermore, some patients
with advanced age and severe comorbidities often
caused by substance abuse do not qualify for this treat-
ment. Besides such clinical risk factors, single nucleotide
polymorphisms (SNPs) of genes influencing the mode of
action or the metabolism of cytotoxic drugs may identify
patients, who on the one hand have more benefit from
intensive treatment or on the other hand are at higher
risk for toxicity. Three SNPs of the DNA repair genes
ERCC1, ERCC2 and XRCC1 influencing the efficacy of
cisplatin have been described to predict better outcome
in a heterogeneous cohort of 103 patients with head and
neck cancer treated with cisplatin during induction
chemotherapy or RT [7]. Nevertheless, this report in-
cluded only 40 patients treated with modern induction
chemotherapy with cisplatin, fluoropyrimidine and tax-
anes. Furthermore, data on the influence of genetic
polymorphisms on the incidence of treatment related
toxicities are still missing. Docetaxel-induced toxicity,
especially bone marrow suppression, is reported to be
influenced by such polymorphisms [8–11].
To test the value of these polymorphisms for predict-
ing the efficacy and toxicity of the TPF regimen we
assessed the clinical outcome and the genetic signature
of 6 genes in all patients treated with TPF therapy for




All patients included for this analysis were diagnosed
with advanced head and neck cancer between January
2006 and December 2013 and consecutively treated with
TPF chemotherapy as first line therapy treatment at the
3rd Medical Department of the Paracelsus Medical
University Salzburg. Follow-up data were available for all
patients at the last update of the database on the 28th of
February 2014. Clinical data were also obtained by tele-
phone interviews of the general practitioners or rela-
tives if needed. Three cycles of induction treatment
including docetaxel (75 mg/m2), cisplatin (75 mg/m2)
and 5-fluorouracil (750 mg/m2 continously for 5 days)
were planned in all patients in analogy to the TAX 323
trial [4] as our local standard. Primary use of granulocyte-
colony stimulating factor support was mandatory and all
patients were hospitalized at least for the first cycle of
treatment until bone marrow recovery. Prophylactic anti-
biotic treatment using a fluoroquinolone was also an insti-
tutional practice. Response to induction chemotherapy
was clinically assessed before each cycle and radiologic re-
sponse was assessed after 2 or 3 cylces with the method,
which was used for primary staging (magnetic resonance
imaging in 82 % of all cases).
After completion of induction chemotherapy all pa-
tients were referred for concomitant radiotherapy in
combination systemic treatment (cisplatin, carboplatin
cetuximab). Patients without response to induction che-
motherapy after two cycles were referred for salvage sur-
gery or immediate radiotherapy if unresectable.
This retrospective study was approved by the Ethics
Committee of the provincial government of Salzburg,
Austria (415-EP/73/340-2014) and written informed
consent was obtained from all patients. Clinical data in-
cluding the stage of disease, loco regional control (LRC),
OS and progression free survival (PFS) were analyzed by
chart based review. PFS was calculated from start of
therapy until disease progression, diagnosis of another
tumor or death from any cause. Common toxicity cri-
teria for adverse events version 4.0 (CTCAE 4.0) were
used to assess treatment related toxicity.
Statistical analyses were performed using IBM® SPSS®
statistics software, version 20. Mann–Whitney-U-test and
Pearson’s chi-squared test were used for univariate ana-
lyses, where appropriate. Survival was estimated using
Kaplan-Meier curve analysis, with statistical comparison
using the log-rank statistic. A two-tailed significance-level
of 0.05 was considered statistically significant. Only statis-
tically significant factors were included into multivariate
Cox-regression analyses. Due to the exploratory and hy-
pothesis generating design of the present SNP data study
no adjustment for multiple testing was applied [12].
SNP genotyping
SNPs influencing the pharmacodynamics of cytotoxic
agents were chosen for analysis after extensive review of
the available literature dealing with the metabolism of
drugs within the TPF regimen. The following SNPs were
selected because of reported effect on drug efficacy:
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ERCC2-rs13181 and rs1799793, ERCC1-rs3212986 and
rs11615, XRCC1-rs25487 [7, 13]. The CYP39A1-rs7761731
and SLCO1B3 rs11045585 polymorphisms are reported
to be associated with treatment related toxicity caused
by docetaxel, which is the major component of
hematological toxicity in the used induction chemo-
therapy regimen [8–11].
Germ line DNA was extracted from frozen peripheral
blood cells in 65 % of the patients. In the other patients
without frozen peripheral blood cells we used extracted
germ line DNA from diagnostic formalin fixed tissue
samples with no histologically observed tumor infiltra-
tion. This procedure was performed using the Maxwell
16 FFPE Plus LEV or Maxwell Blood DNA Purification
KIT. Extracted DNA was amplified using the Geno-
typing Master Mix and SNP Genotyping assay from
TaqMan®. Afterwards allelic discrimination was per-
formed using the software of the Applied Bio System
7500 system (Thermo Fischer). The assessed genotypes
were correlated and then subjected to correlative ana-
lyses with the clinical outcome of the patients (LCR,




All 78 patients recruited in the study were consecutively
treated with TPF induction chemotherapy for advanced
head and neck cancer between 2006 and 2013 (see
Table 1). In detail, all patients were Caucasians with a
median age of 56.0 years and 88.5 % of the patients were
male. As expected, the majority of the patients (80.7 %)
had a primary tumor of the pharynx, 15.4 % were diag-
nosed with a tumor of the oral cavity. Squamous cell
carcinoma was diagnosed in 98.7 % of the patients and
all except for one were HIV negative. Median follow-up
for alive patients was 56 months.
Clinical outcome in patients treated with TPF
The median PFS and OS of all patients treated with at
least 1 cycle of TPF were 20 and 31 months, respectively
(see Fig. 1). Overall response rate (ORR) after chemo-
therapy was 78.1 % including partial remission (PR) in
63 % and complete response (CR) in 15 % of the
patients; 13.7 % had stable disease and 8.2 % of the 73
evaluable patients had refractory disease following
induction chemotherapy. The therapy following TPF was
RT in 88.5 %, surgery of the primary tumor in 5.1 and
6.4 % of the patients received no further treatment due
to toxicity or progression (see Table 1). As expected, the
presence of AJCC stage 4 disease or a cT4 primary
tumor had negative influence on the clinical outcome
of the patients (median PFS not reached vs. 17 months
p = 0.026; 50 vs. 13 months p = 0.045), respectively.
Nevertheless, multivariate analyses failed to show an
independent value of one of these factors, respectively
(p = 0.263; p = 0.116).
Sixty-eight of these 69 patients receiving RT after TPF
were treated with a concomitant regimen during RT. As
concomitant therapy for RCTX, high dose cisplatin, car-
boplatin and cetuximab were used in 67.7, 14.7 and
17.6 % of the patients.
Concomitant cisplatin treatment during RT was asso-
ciated with better LRC (49 vs 11 months p < 0.001), PFS
(36 vs 9 months p < 0.001) and OS (60 vs 19 months
p = 0.005) than treatment with another drug regimen.
To evaluate a possible influence of the previous response
to induction therapy on the choice of concomitant treat-
ment we also evaluated only patients with a response to
TPF. Concomitant cisplatin treatment was also associated







>60 years (%) 28.2
Sex
Male n = 69 (88.5 %)
Female n = 9 (11.5 %)
Treatment after TPF (%)
RT n = 69 (88.5 %)
OP n = 4 (5.1 %)
no further treatment due to toxicity n = 5 (6.4 %)
Nodal stage cN2c or cN3
Yes n = 24 (30.8 %)
No n = 54 (69.2 %)
cT4 stage (%)
Yes n = 53 (67.9 %)
No n = 25 (32.1)
Stage of disease
AJCC Stage 4 n = 73 (93.4 %)
AJCC Stage 3 n = 5 (6.4 %)
Localisation of primary tumor (%)
Oral cavity n = 12 (15.4 %)
Pharynx n = 63 (80.7 %)
Paranasal sinus n = 2 (2.6 %)
Not available n = 1 (1.3 %)
TPF docetaxel, 5-flurouracil, cisplatin
CUP carcinoma of unknown primary
RT radiotherapy
n number
AJCC American Joint Committee on Cancer
Melchardt et al. BMC Cancer  (2015) 15:725 Page 3 of 7
with a better LRC (59 vs 18 months p = 0.022) and better
PFS (49 vs 14 months p = 0.024) in these patients, but OS
did not reach statistical significance (60 vs 27 months
p = 0.094).
SNP analysis in patients treated with induction
chemotherapy
Germ line DNA for analysis of the 6 SNPs rs13181,
rs1799793, rs3212986, rs11615, rs25487, rs7761731 were
available for all patients treated with TPF chemotherapy.
Despite the limited size of the cohort all SNPs were
present at the predicted Hardy-Weinberg equilibrium
and the allele frequencies were in line with the published
databases (see Table 2). None of the SNPs especially
those, who were previously described to be relevant for
treatment efficacy, had a significant influence on LRC,
PFS or OS in our cohort. We also could not observe any
difference in the ORR.
Toxicity in patients treated with induction chemotherapy
Overall, 204 cycles of TPF were administered in 78
patients with 73.1 % of patients receiving all of the three
planned cycles of therapy. Nevertheless, due to excessive
toxicity 11.5 % of the patients received only one cycle
of therapy. Therapy related complications (myocardial
infarction, 2 septic complications) resulted in 3 deaths
during induction chemotherapy (treatment related mor-
tality: 3.8 %). Furthermore, one patient committed suicide
after the first cycle of therapy and one patient developed a
progressive confusional state after the first cycle of treat-
ment and successful bone marrow recovery without infec-
tious complication and died 2 months later (see Tables 3
and 4). A grade 3 or 4 leucopenia after the first cycle of
treatment was observed in 44.7 % of the 76 evaluable pa-
tients, but none of them experienced grade 3 or 4 throm-
bopenia. Grade 3 or 4 infection was observed after 28 of
202 (13.8 %) evaluable cycles of induction therapy and in
22 of 76 (28.9 %) evaluable patients. Renal toxicity higher
than grade 1 was documented in 9 out of 202 (4.4 %)
cycles in 9 different patients (see also Tables 3 and 4).
Beside the tested polymorphisms associated with drug
efficacy described above we also tested two polymor-
phisms related to docetaxel related toxicity.
The rs7761731 SNP of the CYP39A1 gene is reported to
be associated with a higher rate of leucopenia in patients
treated with docetaxel [8]. Therefore, we evaluated its
a
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Fig. 1 Clinical outcome in patients treated with induction chemotherapy. PFS (median 20 months a) and OS (median 31 months b) in all patients
treated with first line TPF induction chemotherapy
Table 2 Allele frequency
SNP n Genotype frequency HWE (p)
rs13181 ERCC2 78 19 GG (24.4 %) 35 GT (44.9 %) 24 TT (30.8 %) 0.53
rs3212986 ERCC1 78 10 AA (12.8 %) 24 AC (30.8 %) 44 CC (56.4 %) 0.72
rs 11615 ERCC1 78 27 AA (34.6 %) 36 AG (46.2 %) 15 GG (19.2 %) 0.58
rs 1799793 ERCC2 78 25 CC (32.1 %) 40 AG CT (51.3 %) 13 TT (16.7 %) 0.58
rs 7761731 CYP39A1 77 33 AA (42.9 %) 36 AT (46.8 %) 8 TT (10.4 %) 0.66
rs 25487 XRCC1 78 36 CC (46.2 %) 36 CT (46.2 %) 6 TT (7.7 %) 0.69
rs11045585 SLCO1B3 77 49 AA (63.8 %) 26 AG (33.3 %) 2 GG (2.6 %) 0.50
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influence on the frequency of leucopenia in our patients.
Homozygosity of allele A, T and heterozygosity were ob-
served in 42.9, 10.4 and 46.8 % of the patients, respectively
(see Table 2). As expected, this polymorphism had no in-
fluence on the clinical outcome of patients, Patients with
homozygosity for allele A had a significantly higher rate of
grade 3 or 4 leucopenia during the first cycle com-
pared to patients with genotype AT and TT (62.5 %
vs 32.5 % p = 0.01). This negative effects of allele A also
persists comparing the frequency of leucopenia during the
first cycle with patients with genotype AA and AT to
patients with genotype TT (49.2 % vs 12.5 % p = 0.048).
We also observed a higher rate of a combined endpoint of
infections or death during induction chemotherapy in pa-
tients with homozygosity for allele A compared to patients
with genotype AT and TT (45.4 % vs 22.7 % p = 0.035).
Furthermore, we evaluated the influence of the
SLCO1B3 rs11045585 polymorphism. This gene encodes
a solute carrier organic anion transporter member,
which is expressed specifically in the basolateral mem-
brane of hepatocytes and was previously reported to
affect toxicity caused by docetaxel [9, 14]. Homozygosity
of allele A, G and heterozygosity were observed in 63.6,
2.6 and 33.8 % of the patients, respectively (see Table 2).
No influence of the rs11045585 polymorphism on the
frequency of leucopenia after the first or entire induction
chemotherapy (p = 0.925; p = 0.99) or grade 3 or 4 infec-
tion (p = 0.77) was observed.
Discussion
Despite improvements of supportive care in medical on-
cology treatment related toxicity remains a major obs-
tacle in patients with advanced head and neck cancer.
Therefore, a more precise clarification of the benefits of
intensive induction chemotherapy and concomitant drug
regimens during RT is needed.
Our cohort of consecutively treated patients represents
one of the largest cohorts treated outside a clinical trial
with TPF. The clinical data with a median PFS of
20 months, a median OS of 31 months and a treatment
related mortality of 3.8 % related to TPF are in line with
the published data from clinical trials and retrospective
analyses [3, 4, 15–18]. The ORR to induction chemo-
therapy was high and the vast majority of patients were
referred for further RT as planned.
Despite this multimodality treatment is a standard op-
tion in patients with advanced head and neck cancer, the
role of the concomitant cytotoxic agents after induction
chemotherapy is less clear. In combination with postop-
erative and definitive RT high dose cisplatin therapy is
considered as gold standard in feasible patients [19, 20],
but a recent phase 2 trial doubted its role in comparison
to cetuximab after induction chemotherapy [21]. Be-
cause of suggested higher efficacy concomitant cisplatin
therapy is considered as treatment standard after induc-
tion chemotherapy in our cancer center in fit patients
without contraindications for or severe toxicities during
induction chemotherapy. This intensive management
was associated with a better clinical outcome than treat-
ment with carboplatin or cetuximab. To exclude a bias
of patients, who were switched to cetuximab because of
a lack of response to cytotoxic induction therapy we also
analyzed only the subgroup of patients, who achieved at
least a PR after induction therapy. Cisplatin was also as-
sociated with a better LRC and PFS than non-intensive
therapy, but OS did not reach statistical significance in
these patients. Therefore, we continue to use cisplatin as
concomitant regimen after induction chemotherapy in
patients without contraindications. Nevertheless, we
want to point out a selection bias in this analysis due to
the fact that only patients in good clinical condition
were considered for this intensive treatment with high
dose cisplatin during RT.
Besides clinical risk factors such as age or comorbi-
dites, the tolerance and efficacy of cytotoxic drugs may
be influenced by SNPs of genes involved in drug metab-
olism. Polymorphism of the ERCC2 and XPD gene have
been described to associated with a better OS in patients
treated with various cisplatin based chemotherapy regi-
mens, but only 40 patients were treated with modern in-
duction chemotherapy including taxanes [7]. We tested
these SNPS together with polymorphisms of the ERCC1
gene, which are also associated with a better outcome
Table 4 Toxicity during induction chemotherapy according to




AA (n = 33 AT (n = 36) TT (n = 8)
Leucopenia G3/4 (%) 65.6 % 45.7 % 37.5 % 52.6 %
Infection G3/4 (%) 40.6 % 20.0 % 25.0 % 28.9 %
Renal Toxicity > G1 (%) 6.3 % 14.3 % 12.5 % 11.8 %
Thrombopenia G3 (%) na. 2.8 na. 1.3 %
na. not available
Table 3 Toxicity during first cycle of induction chemotherapy





AA (n = 33 AT (n = 36) TT (n = 8)
Leucopenia G3/4 (%) 62.5 % 37.1 % 12.5 % 44.7 %
Infection G3/4 (%) 28.1 % 20.0 % 25.0 % 23.1 %
Renal Toxicity > G1 (%) 3.1 % 11.4 % 12.5 % 9.2 %
Thrombopenia G3 (%) na. na. na. 0 %
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with cisplatin based treatment [13], in our cohort of 78
uniformly treated patients with TPF, but we could not
reproduce any association of a certain polymorphism
with the clinical outcome.
We further tested the influence of the CYP39A1-
rs7761731 and SLCO1B3-rs11045585 polymorphisms on
adverse effects during TPF chemotherapy. The addition
of docetaxel to cisplatin and 5-fluorouracil nearly dou-
bled the rate of leucopenia in two randomized trials and
therefore a genomic marker to identify patients at high
risk for leucopenia would be useful. CYP39A1 is a
microsomal cytochrome P450 enzyme and is expressed
in the liver, where docetaxel is mainly metabolized. It is
involved in the conversion of cholesterol to bile acids.
There is one report so far published that genotype A of
this gene was associated with neutropenia after doce-
taxel treatment in Japanese patients with gynecological
malignancies [8]. We could show now for the first time
that Caucasian patients with both genotypes AA and AT
are more prone to severe leucopenia in the first cycle of
TPF treatment in comparison to patients with TT geno-
type despite prophylactic growth factor use in all pa-
tients. We also observed a higher rate of infections or
death during TPF in patients with the genotype AA
despite antibiotic prophylaxis. Nevertheless, we could not
reproduce the effect of the SLCO1B3 rs11045585 poly-
morphism on docetaxel-induced leucopenia reported in
previous literature [9–11]. It remains unclear, if this effect
was diminished by the use of prophylactic growth factor
or the combined effect of 3 cytotoxic drugs.
Our work has several limitations. Despite the fact that
we provided a detailed follow-up of all consecutively
treated patients this analysis may imply an operative se-
lection bias. The size of our cohort is larger than most
of the published retrospective cohorts of patients treated
with TPF [15–18], but of course cannot be compared
with large phase 3 trials [3, 4]. Absolute neutrophil
counts in addition to leukocytes counts would have been
desirable, but were not available for the majority of
patients, because the total leukocyte count is often com-
pletely sufficient in clinical practice. Nevertheless, docu-
mentation of toxicity was precise, especially in the first
cycle of treatment because of hospitalization of all pa-
tients until bone marrow recovery with routine blood
count testing at least every other day. Assessment of the
HPV status was not available in this analysis, but this
has no proven value for the choice of induction chemo-
therapy during clinical routine.
Furthermore, our results suggest a superiority of the
use of concomitant cisplatin in patients already treated
with TPF for subsequent radiochemotherapy. Although
we could show this effect also in patients with a radio-
logical response to TPF, these results may be biased due
to less comorbdities and better performance status in
patients further treated with cisplatin. Therefore, we
think this question will only be clarified in a prospective
randomized clinical trial.
Conclusion
In summary, we could show the feasibility of intensive
induction chemotherapy using the TPF regimen in a
large single center cohort, but significant toxicity despite
growth factor and antibiotic support remains a major
concern in these patients. This is the first report of a
gene polymorphism associated with treatment related
toxicity during induction chemotherapy in patients with
head and neck cancer. This finding is hypothesis-
generating and further evaluation in other larger cohorts
is needed to confirm this observation.
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